Posted on 2/2/14

elderly couple 300LEXINGTON, Ky. (12/8/13) – A new clinical trial being conducted at the University of Kentucky Sanders-Brown Center on Aging and the UK Alzheimer’s Disease Center may signal new hope in the future for those who might be afflicted with the devastating disease. Taking laboratory research pioneered at SBCoA and the associated UK ADC into human trials, the federally-funded research project will examine the therapeutic potential of microRNAs to delay or prevent Alzheimer’s disease.
Led by physician-scientist Dr. Gregory Jicha, and building off of the work of fellow SBCoA physician-scientist Dr. Peter Nelson, the project, formally titled “Modulation of micro-RNA pathways by gemfibrozil in pre-dementia Alzheimer disease,” will operate with a total budget of $1.5 million over three years. Funding was awarded by the National Institute on Aging as the result of a competitive process.
In 2006, the Nobel Prize was awarded for the discovery of microRNA biology. MicroRNAs are now understood by scientists to be implicated in health and disease states for hundreds of conditions. However, despite advances in microRNA technology, to date no group in the world has been able to apply microRNA discoveries in human clinical trials to affect neurodegenerative disease states.
“We are currently funded by the NIA/NIH and approved to take Dr. Pete Nelson's microRNA discoveries into the first-ever human clinical trial of microRNA modulation to influence a disease state. This trial is just starting, but it is not a hope or future expectation, it is real today,” said Jicha. “The microRNA project at the University of Kentucky is the first trial in the history of mankind to test the therapeutic potential of microRNAs in modulating neurodegenerative disease states. If our discovery is successful it will open the door for untold therapeutic developments for the diseases that plague us all as we age.”
As background, Jicha explained that, “Many have heard the speculation that more than 90 percent of our DNA is ‘junk’. The truth is that if we had ‘junk’, it would have been weeded out evolutionarily.”
In reality, at least some of this DNA codes for small fragments of RNA that regulate gene expression in health and disease states. These small RNA fragments are called microRNA. In previous work, Nelson of SBCoA has been able to show that one such microRNA is reduced in the brain very early as Alzheimer’s disease pathology begins.
“Nelson’s evidence suggests that if we can increase the levels of this microRNA, we may be able to prevent Alzheimer’s disease, or even stop it when it is in its earliest stages,” said Jicha.

Fortunately, a FDA-approved drug that can increase miRNA-107 levels already exists, and is currently approved for treating high cholesterol. In cell culture experiments this drug, called gemfibrozil, can prevent Alzheimer’s disease-associated changes.
Gemfibrozil is one of a class of drugs called fibrates, currently used worldwide to treat high cholesterol. Previous studies of people taking fibrates have consistently demonstrated an approximately 50 percent reduction in risk for Alzheimer’s disease.
“In U.S. terms,” said Jicha, “that could potentially cut the burden of Alzheimer’s from 5.4 million cases to 2.7 million nationwide.”
“This innovative clinical trial is a great example of the ‘bench to bedside’ focus of the UK Sanders-Brown Center on Aging – taking a research discovery made in the laboratory and translating that knowledge into a human clinical study. This pioneering clinical study testing the therapeutic potential of microRNAs to delay or prevent Alzheimer’s disease clearly shows how Pete Nelson and Greg Jicha, and the Sanders-Brown Center on Aging, are leading the world in testing promising new approaches to Alzheimer’s therapy,” said Linda Van Eldik, director of the Sanders-Brown Center on Aging.
Watch Dr. Jicha discuss the importance of clinical trials to Alzheimer's research below:

SurfKY News
Information provided by Allison Elliott-Shannon your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

3/13 - 16

Weather Sponsored by

1 DOW 16,776.43
+304.06 (1.85%)    
2 S&P 1,987.05
+35.69 (1.83%)    
3 NASDAQ 4,781.26
+73.49 (1.56%)    

Stock Report Sponsored by

3/13 - 16

Most Read This Week

September 30, 2015 10450

Dawson Woman Dead After Princeton Factory…

by SurfKY News
October 01, 2015 7150

UPDATE: Madisonville Woman Charged after Bank…

by Doreen Dennis, SurfKY News
September 29, 2015 6257

UPDATED: Witness Describes Crash at Dawson…

by Doreen Dennis, SurfKY News
September 30, 2015 4485

Four Arrested After Allegedly Exposing Children…

by SurfKY News
October 01, 2015 3302

Clay Man Charged with Burglaries; Two Charged…

by SurfKY News

Most Read This Month

September 16, 2015 12387

Mining Accident Fatality - Update

by Doreen Dennis, SurfKY News
September 30, 2015 10450

Dawson Woman Dead After Princeton Factory…

by SurfKY News

Stories Trending Now

October 05, 2015 2068

Four Charged with Drug Offenses after Motel…

by SurfKY News
October 04, 2015 1297

Learning More About Childhood Cancer

by KET
October 04, 2015 813

Dave Says - Oct. 4, 2015

by SurfKY News
October 04, 2015 727

Outdoor Truths - Oct. 4, 2015

by SurfKY News
October 04, 2015 600

Man Dies in Early Morning Traffic Accident

by SurfKY News
October 04, 2015 596

TVA Invites Public to Aquatic Health Surveys

by SurfKY News
October 04, 2015 562

Four Injured During Four-Vehicle Collision

by SurfKY News
October 05, 2015 559

UK Biofuels Team Receives Nearly $1 Million from…

by SurfKY News
October 05, 2015 539

Dawson Springs Police Reports Released

by SurfKY News
October 05, 2015 419

Kentucky Lottery Results for Friday Oct. 2, 2015

by SurfKY News